Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Debt to Equity (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Debt to Equity for 4 consecutive years, with $0.0 as the latest value for Q3 2025.

  • On a quarterly basis, Debt to Equity fell 29.4% to $0.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.0, a 29.4% decrease, with the full-year FY2024 number at $0.01, changed N/A from a year prior.
  • Debt to Equity was $0.0 for Q3 2025 at bioAffinity Technologies, up from -$0.02 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.04 in Q3 2022 to a low of -$0.02 in Q2 2025.
  • A 4-year average of $0.01 and a median of $0.01 in 2024 define the central range for Debt to Equity.
  • Biggest YoY gain for Debt to Equity was 663.46% in 2025; the steepest drop was 424.4% in 2025.
  • bioAffinity Technologies' Debt to Equity stood at $0.02 in 2022, then plummeted by 77.07% to $0.01 in 2023, then skyrocketed by 48.36% to $0.01 in 2024, then tumbled by 36.76% to $0.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Debt to Equity are $0.0 (Q3 2025), -$0.02 (Q2 2025), and $0.03 (Q1 2025).